Skip to main content
TipRanks
Go Ultimate75% OFF

Stephen Doberstein Insider Profile

4 Followers

Stephen Doberstein, SVP & Chief Scientific Officer at Nektar Therapeutics, holds 107.67K shares in Nektar Therapeutics (Ticker: NKTR), holds 3.33K shares in Dicerna Pharma (Ticker: DRNA), holds ― shares in Forte Biosciences (Ticker: FBRX). Most recently, Stephen Doberstein Bought ― shares of Nektar Therapeutics on Sep 09, 2019 for an estimated value of $259.20K.

Stephen Doberstein's Trading History

NKTR
Nektar Therapeutics
Sep 09, 2019SVP & Chief Scientific OfficerInformative Buy259.20K$4.01M
FBRX
Forte Biosciences
――――
DRNA
Dicerna Pharma
―――$127.39K

You May Also Like

Stephen Doberstein insider profile FAQ

What is the percentage of profitable transactions made by Stephen Doberstein?
The percentage of profitable transactions made by Stephen Doberstein is 17%.
What is the average return per transaction made by Stephen Doberstein?
The average return per transaction made by Stephen Doberstein is -136.10%.
What stocks does Stephen Doberstein hold?
Stephen Doberstein holds: NKTR, DRNA, FBRX stocks.
What was Stephen Doberstein’s latest transaction?
Stephen Doberstein’s latest transaction was an Informative Buy of $259.20K.
What was Stephen Doberstein's most profitable transaction?
Stephen Doberstein’s most profitable transaction was an Informative Buy of NKTR stock on September 9, 2019. The return on the trade was 5.50%.
What is Stephen Doberstein's role in Nektar Therapeutics?
Stephen Doberstein's role in Nektar Therapeutics is SVP & Chief Scientific Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.